In the phase 3 PROFILE-1014 trial, 343 patients with advanced ALK-positive non-squamous NSCLC, treatment-naïve, were randomized to receive crizotinib or platinum plus pemetrexed chemotherapy, with crossover allowed for patients assigned to the control arm [9]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.